key: cord-0878766-1exe5zaj authors: Yousefifard, Mahmoud; Zali, Alireza; Zarghi, Afshin; Madani Neishaboori, Arian; Hosseini, Mostafa; Safari, Saeed title: Non‐steroidal anti‐inflammatory drugs in management of COVID‐19; a systematic review on current evidence date: 2020-05-27 journal: Int J Clin Pract DOI: 10.1111/ijcp.13557 sha: 7530e1cf140e649ebcb7d668261dbed55177e82f doc_id: 878766 cord_uid: 1exe5zaj BACKGROUND: Since there is still no definitive conclusion regarding which non‐steroidal anti‐inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID‐19. METHODS: A search was performed in Medline (via PubMed), Embase, and CENTRAL databases until 23 March 2020. Clinical trials on application of NSAIDs in viral respiratory infections were included. RESULTS: Six clinical trials were included. No clinical trial has been performed on COVID‐19, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome infections. Studies show that ibuprofen and naproxen not only have positive effects in controlling cold symptoms but also do not cause serious side effects in rhinovirus infections. In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalization in patients with pneumonia due to influenza. CONCLUSION: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID‐19 and case‐reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID‐19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID‐19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials. Ritonavir has been mentioned as the first line of antiviral therapy in protocols, but a clinical trial on 199 patients shows that the outcome of using this combination therapy in severe COVID-19 cases is not different than standard treatment (4) . On the other hand, a case report on 4 young patients with no underlying illness showed that prescription of ibuprofen exacerbates the condition of the patients (5) . These reports have resulted in studies still seeking the optimum treatment for COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) have been used for management of respiratory infections, controlling fever, reducing chest pain and other symptoms such as cough since a long time ago (6, 7) . Many NSAID compounds are available, the most famous of which are ibuprofen, diclofenac, aspirin, naproxen, and indomethacin. Some of the compounds in this family have antiviral properties in addition to anti-inflammatory properties, which makes them appropriate for treating viral respiratory infections (8, 9) . Although these medications have been used in respiratory infections for years, there is still no definitive conclusion regarding which compound is most effective and safe. In a case report on 4 patients with COVID-19, it was shown that ibuprofen might exacerbate the condition of patients (5) . However, some guidelines have recommended prescription of ibuprofen in these patients (2) . Therefore, there is still controversy on which NSAID should be used in the treatment protocol of COVID-19 patients (10) (11) (12) . Large number of articles have been published on COVID-19 in the first 3 months of 2020, most of which have focused on epidemiological evaluation and clinical course and treatment of the disease. In the preliminary search performed by the researchers of the present study it was found that the majority of the studies published on COVID-19 treatment were case-series and case-reports and there are few reports on prescription of NSAIDs in This article is protected by copyright. All rights reserved these studies. Therefore, in the present systematic review we decided to evaluate the effectiveness of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID-19 based on the findings. -Study design The present systematic review aims to evaluate the existing clinical trials on safety and efficacy of using NSAIDs in management of viral respiratory infections. To reach the aims of the present study, a combination of terms related to NSAIDs and viruses causing respiratory infections were used on search databases. Choosing the keywords related to viruses causing respiratory infections was done with the guidance of a respiratory disease specialist and NSAIDs with the consultation of a pharmacologist. In the present study, all clinical trials were included. Animal studies, in vitro evaluations, non-viral infections, non-respiratory infections, observational studies and review studies were excluded. The search strategy used for searching in Medline database has been reported in appendix 1. In addition to the systematic search, a manual search was performed via Google and Google Scholar search engines, and in bibliography of related articles. Records were saved in Endnote X7 and duplicates were removed. In the next step, initial screening was performed by 2 independent researchers. Then, articles were selected based on the inclusion and This article is protected by copyright. All rights reserved exclusion criteria, and data were summarized in a checklist by 2 independent researchers. The gathered data consisted of name of the first author, year of publication, country in which the study was performed, type of study, sample size, age and sex distribution of the patients, name of the virus causing respiratory infection, name of the NSAIDs, dose and duration of prescription, route of administration and treatment outcome. Any disagreement was resolved through discussion with a third reviewer. -Risk of bias assessment of the studies Quality control of the studies was performed based on the guidelines of Cochrane Collaboration's tool for assessing risk of bias in randomised trials (13) . The performed search yielded 1033 non-duplicate articles. Out of which, six clinical trials were finally included in the present study (14) (15) (16) (17) (18) (19) (Figure 1 ). These studies included 845 adult patients (46.9% male). The studied viruses were rhinovirus in four studies, Influenza type A (H3 N2) in one study and unknown in one study. The NSAIDs applied were naproxen in three studies, aspirin in one study, and ibuprofen in two studies. Route of administration was oral in all the studies. The control group was placebo in five studies and oseltamivir in one study. Duration of treatment varied between four and 14 days. In three studies, other drugs were used as combination therapy along with NSAIDs. Table 1 depicts the characteristics of the included studies. -Risk of bias assessment of the articles Risk of bias assessment showed that random sequence generation, blinding of participants and personnel, and other bias had low risk of bias in all studies. Allocation concealment was unclear in two studies. Selective reporting was also unclear in four studies. Finally, blinding of outcome assessment in two studies and incomplete outcome assessment in 1 study were categorized as high risk (Table 2 ). This article is protected by copyright. All rights reserved The included clinical trials had studied different NSAIDs and they had different findings. In the first study, in 1990, Garaham et al. performed a clinical trial on 34 healthy volunteers and after infecting them with rhinovirus showed that prescription of aspirin and acetaminophen could inhibit serum neutralizing antibody response and increase the respiratory symptoms of these patients. However, these variables were not different from those of the placebo group with ibuprofen prescription. In addition there was no difference in viral shedding between the groups under treatment with acetaminophen, aspirin and ibuprofen combination and placebo (16) . In another study, in 1992, Gwaltney performed a similar study on healthy volunteers and showed that naproxen, interferon-α2b and ipratropium combination therapy led to decrease in the time of viral shedding and alleviation of the symptoms of cold. In addition, viral titers in this group was lower than the placebo group. However, antibody responses and antibody titers were not different between the 2 groups (18) . Yet, it is not known that the observed effects are due to naproxen or interferon-α2b and ipratropium. Anyhow, it seems that naproxen does not cause serious side effects in patients affected with rhinovirus. In addition, in 1989, Sperber et al. studied patients with rhinovirus and showed that oral prescription of ibuprofen decreases the severity of the disease and alleviates cold symptoms in patients compared to the placebo group. Prescription of ibuprofen had no side effects in the studied patients (15) . The same researchers performed another study with similar design in 1992 studying naproxen and showed that 5-day prescription of naproxen alleviated cold symptoms compared to placebo but had no effect in viral titer and serum antibody responses (17) . In their study on 217 Influenza A (H3 N2) patients with pneumonia, Hung et al. compared clarithromycin-naproxen-oseltamivir combination therapy with oseltamiviralone alone and expressed that 5-day therapy with these drugs leads to decrease in 30-day and 90-day mortality of patients as well as duration of hospitalization (14) . This article is protected by copyright. All rights reserved days. The rate of adverse effects was reported to be 5% in ibuprofen group and 3% in placebo group (19) . In evaluating the effectiveness of NSAIDs prescription in management of COVID-19, no study was found to point to using these drugs. In the search performed, 1 clinical trial was found on the effect of prescribing antiviral therapy in management of COVID-19, which had not mentioned prescription of NSAIDs (4). No clinical trial was found with the aim of evaluating the effectiveness or safety of NSAIDs prescription in management of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) patients. The present systematic review aimed to evaluate the existing evidence regarding use of NSAIDs in management of viral respiratory. The findings of the present study showed that no clinical trial was performed on patients with COVID-19, SARS and MERS with this aim. Regarding rhinoviruses, 3 studies have reported that ibuprofen and naproxen not only have positive effects in controlling cold symptoms but also do not cause serious side effects. Another clinical trial, which evaluated the effect of clarithromycin, naproxen and oseltamivir combination on pneumonia due to influenza, showed that this treatment leads to decrease in mortality rate and duration of hospitalization. Recently, in a case report, it was revealed that ibuprofen prescription exacerbated the condition of 4 patients with COVID-19 and this led the researchers to recommend not consuming it (5) . For further investigation, the researchers of the present study evaluated all the existing reports on treatment of COVID-19 patients, which led to finding 1 clinical trial (4) and 12 case-report/case-series studies (1, 3, 20-34). There was no mention of prescribing NSAIDs in any of these studies. This might be due to no NSAID being prescribed, which is very unlikely; or it might just be that the authors did not point This article is protected by copyright. All rights reserved out prescribing NSAIDs. In this regard, it is better that researchers of these studies indicate if they have used NSAIDs in treating the patients or not through a letter to editor or commentary. Further searches revealed that in a study, Jin et al. attempted to provide a treatment guideline for COVID -19 patients. In this study, use of ibuprofen has been suggested for controlling the patients' fever (fever over 38.5° Celsius). The researchers of the study express that at the time of designing the study, there was not sufficient evidence on COVID-19. Therefore, the guideline was prepared based on the studies performed on SARS, MERS and Influenza (2) . Based on the search performed for the present systematic review, no clinical trial has been performed on use of NSAIDs in patients with SARS and MERS. Only one study has been performed on influenza type A (H3 N2), which has reported mild to moderate efficacy for naproxen. Therefore, it seems that suggesting consumption of ibuprofen in the mentioned guideline is based on evidence presented in observational studies and not well-designed clinical trials. Since the pathophysiology and transmission of COVID-19 is different from other viruses and it shows significant differences even with other viruses in the same family, such as SARS and MERS, the findings of the studies performed on other viruses may not be generalizable to COVID-19. In addition, since a case-report has been recently published that recommended not using ibuprofen in COVID-19, NSAIDs should be used with caution. Naproxen could be a proper substitute for ibuprofen for controlling patients' fever. In the clinical trials included in this study naproxen was found to be an effective and safe drug for controlling viral respiratory infections. In addition, there are pre-clinical evidence that indicate the antiviral properties of naproxen. For instance, Zheng et al. showed that naproxen shows wide-spectrum antiviral effects in mice with influenza (8) . Naproxen inhibits nucleoprotein binding to RNA and consequently inhibits replication in viruses (35) . Since COVID-19 is an RNA virus, it seems that naproxen is a good option for treating the fever caused by COVID-19 infection. Therefore, there is a need for designing clinical trials to evaluate the safety and efficacy of naproxen in management of COVID-19 patients. Findings of the present study showed that no clinical trial has been performed with the aim of assessing the efficacy and safety of using NSAIDs in COVID-19, SARS and MERS infections. In the This article is protected by copyright. All rights reserved clinical trials performed on rhinovirus and influenza type A, naproxen has been introduced as a safe None. Financial disclosure: There is no financial disclosure. There is no conflict of interest. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved A Diabetic Patient With 2019-nCoV Infection Who Recovered and Was Discharged From Hospital A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists Influence of the nsaids ibuprofen and diclofenac or paracetamolon kidney function in patients with hantavirus infection Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells. Advances in medical sciences Accepted Article This article is protected by copyright. All rights reserved 8 Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export Indomethacin has a potent antiviral activity against SARS coronavirus COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and nonsteroidal anti-inflammatory drugs (NSAID)' by Giollo et al. Annals of the rheumatic diseases The Cochrane Collaboration's tool for assessing risk of bias in randomised trials Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the Accepted Article This article is protected by copyright. All rights reserved treatment of experimental rhinovirus colds Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. The Journal of infectious diseases Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial Combined antiviralantimediator treatment for the common cold Effectiveness of anti-inflammatory treatment versus antibiotic therapy and placebo for patients with non-complicated acute bronchitis with purulent sputum. The BAAP Study protocol Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A report of clinical diagnosis and treatment of 9 cases of coronavirus disease 2019 Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China Accepted Article This article is protected by copyright. All rights reserved Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing ， China. medRxiv Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China The Treatment and Outcomes of Patients with COVID-19 in Hubei, China: A Multi-Centered, Retrospective, Observational Study Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus Pneumonia, Viral"[mh] OR "Respiratory Syncytial Viruses"[mh] OR "Respiratory Syncytial Virus Infections"[mh] OR "Respiratory Syncytial Virus, Human"[mh] OR "Respiratory Syncytial Virus, Bovine"[mh] OR "Rhinovirus"[mh] OR "Influenza, Human"[mh] OR "Influenza A Virus, H10N8 Subtype"[mh] OR "Influenza A Virus, H7N9 Subtype"[mh] OR "Influenza A Virus, H10N7 Subtype"[mh] OR "Influenza A Virus, H7N3 Subtype"[mh] OR "Influenza A Virus, H7N2 Subtype"[mh] OR "Influenza A Virus, H7N1 Subtype"[mh] OR "Influenza A Virus, H1N2 Subtype"[mh] OR "Influenza A Virus, H9N2 Subtype"[mh] OR "Influenza A Virus, H7N7 Subtype"[mh] OR "Influenza A Virus, H5N2 Subtype"[mh] OR "Influenza A Virus, H3N2 Subtype"[mh] OR "Influenza A Virus, H2N2 Subtype Herpesvirus 3, Human"[mh] OR "Varicella Zoster Virus Infection OR Common Cold Virus Influenza B virus[tiab] OR Orthomyxovirus Type B[tiab] OR Influenza Virus Type B Orthomyxovirus Type C[tiab] OR Influenza Virus Type C[tiab] OR Influenza C Virus SARS SARS-Associated Coronavirus This article is protected by copyright. All rights reserved Appendix